Phase I Study of Marizomib + Panobinostat for Children With DIPG (DIPG)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04341311 |
|
Recruitment Status :
Terminated
(Withdrawal of support from BMS)
First Posted : April 10, 2020
Last Update Posted : February 15, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Celgene
Secura Bio, Inc.
Information provided by (Responsible Party):
Katherine Warren, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | February 14, 2024 |
| Actual Study Completion Date : | February 14, 2024 |